This week, we bring you major industry IPOs, inspiring leaders of the new bioeconomy on Spaces, one of the most significant breakthroughs in protein modeling and engineering and much more! Thank you to this week’s sponsorInscripta, who is giving researchers the power to ask trailblazing questions and find solutions to many of today’s pressing challenges with the first benchtop genome engineering platform. With faster engineering cycles and dramatically reduced costs for edit design and generation, the Onyx platform enables
researchers to rapidly improve strains with the freedom of owning their results.See how Sestina Bio has integrated Onyx as a foundational piece of their synthetic biology workflow and is building their strain development pipeline around it.
Early Bird Pricing Flies Away Midnight, July 31st!
Join us today for the Built with Biology show on Twitter Spaces at 8 am PT! Spaces is an audio-only
platform—all you need is a Twitter handle and the Twitter app on your phone.
Today’s show welcomes Marissa Cuevas, founder and CEO of MicroTerra and Osahon Ojeaga, founder of Aja Labs
What’s in a Shape? DeepMind AI Breakthrough Could Transform Biology
In a stunning breakthrough, DeepMind has used its AI to predict the shapes of nearly every protein in the human body, as well as the shapes of hundreds of thousands of proteins found in mice, yeast, and fruit flies. The breakthrough could allow biologists to understand diseases better and develop new drugs.
Spotlight: How is Colorifix Making Sustainable Dyes with Biology?
MeetColorifix, the company dying clothes using pigment-producing microbes to re-color the fashion industry! These microbes are a drop-in solution to replace chemical dyes, save water, and brighten up our style with biology! Listen to the latest episode here!
John Cumbers for Forbes
Scalable Automation is Breaking the Bottleneck on Cell Therapy Manufacturing Manufacturing therapies are difficult and capacity is limited. Now Cellares, a life science technology company, has developed a “factory in a box” for cell therapy
manufacturing. This scalable technology looks to dramatically reduce the cost of these critical treatments and make them accessible for tens of thousands of patients.
Science News
21st Century Olympic Doping: Gene editing for performance enhancement may not be the Tokyo cheat, but we asked the experts how far off it might be.
After years of using the gene-editing technique CRISPR to genetically modify everything from vegetables to lab rodents to humans, researchers have used it to edit one of their hardest targets yet: marsupials.
Funding News
Congratulations to Absci CEO and founder Sean McClain for ringing the closing bell on the NASDAQ on Thursday, July 22, with his team as the biotech company went public with a $200 million IPO. The drug development platform company has a market capitalization of nearly $2
billion.
Congratulations to Caribou Biosciences CEO Rachel Haurwitz. The CRISPR biotech company raised a $304 million IPO to develop cell therapies. Caribou’s shares began trading on the Nasdaq Friday under the
stock symbol “CRBU.”
Genomatica raised $118 million to scale up production of BDO and other bio-based materials for use in personal care and beauty products, and a bio-based nylon for carpets, clothing and engineered plastics.
Nobell Foods raised $75 million to introduce delicious cheeses made from plant-derived dairy proteins, supporting its larger mission of creating a radically more humane and sustainable food system.
